In vitro glucocorticoid sensitivity and improvement in HAQ-DI score in patients with established rheumatoid arthritis (FLARE study). Boxplots (each box shows the mean and interquartiles) and outliers (●) of IL-2-EC50 (A), GILZ-EC50 (B), number of GRs (C) and KD of the GRs (D) in HAQ-DI responders and HAQ-DI-nonresponders. Patients are defined as responders if their HAQ-DI sum scores were at least 0.25 lower after GC therapy.
Quax et al. Arthritis Research & Therapy 2012 14:R195 doi:10.1186/ar4029